Drug Analysis: Auryxia

Drug Analysis: Auryxia

  • January 2018 •
  • 14 pages •
  • Report ID: 5336413 •
  • Format: PDF
Drug Overview
Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease. The drug dissociates into ferric iron and citrate after administration.

Ferric iron is transported to erythroid precursor cells to be incorporated into hemoglobin, and also binds dietary phosphate in the gastrointestinal tract, precipitating as ferric phosphate. This compound is excreted, decreasing the phosphate concentration in the serum.